BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,039 filers reported holding BAXTER INTL INC in Q1 2015. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $206,000 | -92.6% | 2,394 | -94.0% | 0.02% | -96.7% |
Q2 2015 | $2,775,000 | +2.4% | 39,674 | +0.3% | 0.75% | +0.3% |
Q1 2015 | $2,710,000 | -5.0% | 39,570 | +1.7% | 0.74% | -7.8% |
Q4 2014 | $2,853,000 | -3.9% | 38,925 | -5.9% | 0.81% | +5.6% |
Q3 2014 | $2,969,000 | -0.8% | 41,370 | -0.0% | 0.76% | -1.4% |
Q2 2014 | $2,993,000 | -2.5% | 41,385 | -0.8% | 0.78% | -9.7% |
Q1 2014 | $3,069,000 | +13.2% | 41,712 | +7.0% | 0.86% | +14.5% |
Q4 2013 | $2,711,000 | – | 38,982 | – | 0.75% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |